BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37116489)

  • 1. Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis.
    Piper M; Hoen M; Darragh LB; Knitz MW; Nguyen D; Gadwa J; Durini G; Karakoc I; Grier A; Neupert B; Van Court B; Abdelazeem KNM; Yu J; Olimpo NA; Corbo S; Ross RB; Pham TT; Joshi M; Kedl RM; Saviola AJ; Amann M; Umaña P; Codarri Deak L; Klein C; D'Alessandro A; Karam SD
    Cancer Cell; 2023 May; 41(5):950-969.e6. PubMed ID: 37116489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective targeting of IL2Rβγ combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC.
    Gadwa J; Amann M; Bickett TE; Knitz MW; Darragh LB; Piper M; Van Court B; Bukkapatnam S; Pham TT; Wang XJ; Saviola AJ; Deak LC; Umaña P; Klein C; D'Alessandro A; Karam SD
    Cell Rep Med; 2023 Aug; 4(8):101150. PubMed ID: 37586327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8
    Tichet M; Wullschleger S; Chryplewicz A; Fournier N; Marcone R; Kauzlaric A; Homicsko K; Deak LC; Umaña P; Klein C; Hanahan D
    Immunity; 2023 Jan; 56(1):162-179.e6. PubMed ID: 36630914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1-cis IL-2R agonism yields better effectors from stem-like CD8
    Codarri Deak L; Nicolini V; Hashimoto M; Karagianni M; Schwalie PC; Lauener L; Varypataki EM; Richard M; Bommer E; Sam J; Joller S; Perro M; Cremasco F; Kunz L; Yanguez E; Hüsser T; Schlenker R; Mariani M; Tosevski V; Herter S; Bacac M; Waldhauer I; Colombetti S; Gueripel X; Wullschleger S; Tichet M; Hanahan D; Kissick HT; Leclair S; Freimoser-Grundschober A; Seeber S; Teichgräber V; Ahmed R; Klein C; Umaña P
    Nature; 2022 Oct; 610(7930):161-172. PubMed ID: 36171284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
    Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy.
    Waldhauer I; Gonzalez-Nicolini V; Freimoser-Grundschober A; Nayak TK; Fahrni L; Hosse RJ; Gerrits D; Geven EJW; Sam J; Lang S; Bommer E; Steinhart V; Husar E; Colombetti S; Van Puijenbroek E; Neubauer M; Cline JM; Garg PK; Dugan G; Cavallo F; Acuna G; Charo J; Teichgräber V; Evers S; Boerman OC; Bacac M; Moessner E; Umaña P; Klein C
    MAbs; 2021; 13(1):1913791. PubMed ID: 33974508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
    Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
    J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.
    Klein C; Waldhauer I; Nicolini VG; Freimoser-Grundschober A; Nayak T; Vugts DJ; Dunn C; Bolijn M; Benz J; Stihle M; Lang S; Roemmele M; Hofer T; van Puijenbroek E; Wittig D; Moser S; Ast O; Brünker P; Gorr IH; Neumann S; de Vera Mudry MC; Hinton H; Crameri F; Saro J; Evers S; Gerdes C; Bacac M; van Dongen G; Moessner E; Umaña P
    Oncoimmunology; 2017; 6(3):e1277306. PubMed ID: 28405498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.
    Rosen DB; Kvarnhammar AM; Laufer B; Knappe T; Karlsson JJ; Hong E; Lee YC; Thakar D; Zúñiga LA; Bang K; Sabharwal SS; Uppal K; Olling JD; Kjaergaard K; Kurpiers T; Schnabel M; Reich D; Glock P; Zettler J; Krusch M; Bernhard A; Heinig S; Konjik V; Wegge T; Hehn Y; Killian S; Viet L; Runz J; Faltinger F; Tabrizi M; Abel KL; Breinholt VM; Singel SM; Sprogøe K; Punnonen J
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35817480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
    Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition.
    Codarri Deak L; Hashimoto M; Umaña P; Klein C
    Oncoimmunology; 2023; 12(1):2197360. PubMed ID: 37025392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
    Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
    Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.
    Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS
    Front Immunol; 2020; 11():7. PubMed ID: 32117218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
    Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
    Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
    Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
    Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
    Front Immunol; 2018; 9():1955. PubMed ID: 30214445
    [No Abstract]   [Full Text] [Related]  

  • 20. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
    Nelson A; Gebremeskel S; Lichty BD; Johnston B
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.